Last updated: May 25, 2026
Nirogacestat hydrobromide supply chain visibility is low in public sources. Patent and regulatory records do not reliably identify nirogacestat hydrobromide API or finished-dose contract manufacturing organizations (CMOs) tied to a specific commercial launch. With no verifiable supplier list from Orange Book/Drugs@FDA labeling manufacturing sections or publicly attributable filings for the marketed product, no complete or accurate supplier mapping can be produced.
What companies supply nirogacestat hydrobromide API and finished dosage forms?
No complete, source-verifiable supplier roster for nirogacestat hydrobromide (API) and drug product (tablets/capsules) can be stated from public, attributable records.
What role do API suppliers play for nirogacestat hydrobromide?
- API suppliers provide nirogacestat hydrobromide drug substance used to manufacture the final dosage form.
- For a defensible supplier list, the API manufacturer must be explicitly identified in: FDA labeling manufacturing sections, site-specific NDA/BLA technical documentation available via public FDA review, or patent prosecution histories tied to commercial supply.
What role do CMOs play for nirogacestat hydrobromide tablets/capsules?
- Drug-product CMOs typically handle blending, granulation, tableting, coating, packaging, and release testing.
- A supplier answer must name the specific site(s) and legal entities, not generic procurement categories.
What patents or regulatory filings identify nirogacestat hydrobromide manufacturers?
A patent landscape alone does not confirm which entities manufacture the commercial nirogacestat supply.
Does the Orange Book list nirogacestat hydrobromide manufacturing sites?
Orange Book listings identify approved drug products and application numbers and, in many cases, holder(s), but they do not consistently disclose site-level API/drug-product manufacturers for investigational or non-blockbuster products. For a supplier list, the application’s labeling manufacturing section or specific FDA documents are required.
Do Drugs@FDA labeling and prescribing information list CMOs for nirogacestat hydrobromide?
Supplier names sometimes appear in prescribing information under “Manufactured for” or “Manufactured by,” but those must be verified for the specific approved product and strength/dosage form.
Who makes nirogacestat hydrobromide for clinical trials versus commercial supply?
Clinical supply suppliers can differ from commercial supply suppliers. A supplier list must be tied to the specific phase (Phase 1/2/3) and product identity. Without source-verifiable trial-to-commercial mappings, no accurate list can be provided.
Which contract manufacturers are listed for CDK26 inhibitor manufacturing (nirogacestat hydrobromide)?
No source-verifiable list of contract manufacturers can be produced.
What generic or biosimilar entrants could procure nirogacestat hydrobromide from?
No defensible procurement map can be created without:
- confirmed dosage form and strength for the approved product,
- Orange Book status indicating patent-protected forms and exclusivity,
- and verifiable manufacturing-site data for the innovator and potential ANDA filers.
How do patent estate and manufacturing IP affect supply sourcing for nirogacestat hydrobromide?
Patent and manufacturing method coverage can constrain:
- crystallization forms and salt processes for hydrobromide,
- solid-state forms and particle-size distributions,
- and formulation manufacturing steps.
But method patents do not reliably identify actual suppliers.
What is the risk of supplier concentration for nirogacestat hydrobromide?
Without identifiable supplier entities, concentration risk cannot be quantified.
Key Takeaways
- A source-verifiable, complete supplier list for nirogacestat hydrobromide API and finished dosage forms cannot be produced from public regulatory or patent records in the absence of identifiable manufacturing-site disclosures tied to the marketed product.
- Any named supplier list would risk being inaccurate or mixing investigational suppliers with commercial supply.
FAQs
Which companies manufacture nirogacestat hydrobromide drug substance?
No source-verifiable manufacturer list is available for a complete answer.
Which CMOs make nirogacestat hydrobromide tablets for the US market?
No source-verifiable CMO list is available for a complete answer.
Does the nirogacestat hydrobromide Orange Book entry show the API manufacturer?
Public Orange Book entries typically do not provide site-specific API manufacturer data needed for a supplier list.
Are nirogacestat hydrobromide suppliers different for clinical versus commercial supply?
They can be, but a verified supplier-to-phase mapping is not available from public records for a complete answer.
Can patents identify the commercial manufacturer of nirogacestat hydrobromide?
Patents often identify inventors and assignees, not necessarily the commercial API/CMO manufacturing entities.
References
No sources were cited.
